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ABSTRACT 
When superparamagnetic nanoparticles are loaded within micro-carriers of 
thermosensitive and injectable biopolymers, “smart” microdevices are obtained: they respond 
to an external magnetic field (EMF) through the release of any co-encapsulated molecules 
with a remote on-off control.  
Creating reliable and effective fabrication technologies for the production of these 
smart nano/micro-devices remains a challenge. In this work Supercritical Emulsion 
Extraction technology (SEE) is proposed for the fabrication of microcapsules with a core of 
poly-lactic-co-glycolic acid (PLGA) or poly-lactic acid (PLA) covered by carboxybetaine-
functionalized chitosan (f-chi) and loaded with paramagnetic nanoparticles (MAG, mean size 
of 6.5±3.0 nm) and water soluble fluorescein (Fluo). Fluo is co-encaspulated as a fluorescent 
marker for the release study.  
Microcarriers showed a mean size of 800±60nm with an encapsulation efficiency of 
up to 90%. The inversion of surface charge, after the f-chitosan coating, suggested the 
presence of a uniform functionalized surface available for further chemical linkage. The 
external chitosan layer had a thickness of 200±50nm. An excellent MAG dispersion was 
confirmed within the biopolymer matrix that was shown to be responsive to EMF; indeed, 
Fluo was released over 3 or 5 days from PLGA or f-chiPLGA microdevices into PBS 
medium at 37°C; whereas, remote on-off controlled release was achieved when an 
Alternating Magnetic Field (AMF)  was applied. 
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INTRODUCTION 
Superparamagnetic nanoparticles embedded within biopolymer microcarriers may 
offer several therapeutic advantages in a number of clinical applications. The biopolymer 
coating can enhance their biocompatibility, prevent leaching and improve dispersability1-2; 
additionally, in the case of thermosensitive behavior of the biopolymer chosen for coating, a 
fixed dose of the co-encapsulated molecule can be released by remote control3-4. 
The possibility of treating cancer by induced hyperthermia has led to the development 
of many different devices designed to heat malignant cells while sparing surrounding healthy 
tissue5-6. The frequency and strength of the externally applied magnetic field is obviously 
limited by deleterious physiological responses to high frequency magnetic fields7-8. However, 
hyperthermia can be an effective local adjuvant therapy for carcinomas and sarcomas; as an 
example, a randomized phase III trial showed that regional hyperthermia combined with neo-
adjuvant chemotherapy for soft tissue sarcomas resulted in better local progression-free 
survival than chemotherapy alone9. Several reports suggested that hyperthermia for 
osteosarcoma achieved an effective response, including the induction of apoptosis10 and 
inhibition of tumor proliferation11 and DNA synthesis12 in vitro. Regional hyperthermia using 
an alternating magnetic field reduced the pulmonary metastasis of osteosarcoma in an in vivo 
study13. Recent studies indicated that hyperthermia contributes to the improvement of the 
prognosis of patients with soft tissue sarcomas; however, few reports have evaluated the 
impact of hyperthermia on tumor cell motility, which is an important factor of metastasis14.  
The use of a targetable magnetic device is an appealing treatment option as it can 
offer a better way of ensuring that the intended target tissue is heated and/or a localised drug 
delivery is obtained by an on-demand actuation mechanism. The second option is obtained 
using thermosensitive polymers15 or silica16, which can serve as coating materials for 
magnetic nanoparticles and trigger the release of a drug in an on-off mode in response to a 
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magnetically induced increase of temperature. A large variety of magnetic microdevices have 
been proposed in the literature to deliver drugs to specific target sites. Generally, the 
magnetic component of the particle is coated with a biocompatible polymer to shield the 
magnetic particle from the surrounding environment17-19 and/or can also be functionalized by 
attaching carboxyl or amine groups20. Magneto liposomes21 and porous metallic 
nanocapsules22 have also been described.  
In vivo studies utilising magnetic carriers loaded with doxorubicin have already been 
applied to sarcoma tumors implanted in rat tails23 and the initial results were encouraging, 
showing a total remission of the sarcomas compared to no remission in another group of rats 
which were administered with ten times the drug dose but without magnetic targeting. In 
addition, success in cytotoxic drug delivery and tumor remission has been reported by several 
groups using animal models including rats24 and swine25. More recently, an in vitro study 
reported that magnetic poly-lactide-co-glycolide nanocarriers co-encapsulated with 
doxorubicin were easily internalized into murine Lewis lung carcinoma cells inducing 
apoptosis26. Other authors have described magnetic microdevices with functional properties 
of magnetic resonance imaging27 or as magnetic actuation for noninvasive remote-controlled 
drug release28 or as on-demand release of multifunctional nanocapsules29.  
Due to its significant biodegradability and biocompatibility, PLGA/PLA has been 
approved in drug delivery systems for parenteral administration by the FDA and the 
European Medicine Agency. Moreover, the possibility of sustained release and targeted nano 
and microparticle delivery to specific organs or cells lends these materials to other clinical 
applications. As a consequence, poly-lactide (PLA) and its glycolide co-polymer (PLGA) 
have been utilized as a magnetide carrier and different fabrication technologies have been 
described including a single step coaxial electro-hydrodynamic atomization technique30 (Gun 
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et al., 2013), conventional solvent evaporation methods31-38, supercritical technology39 and 
chemical synthesis40-41.  
An engineered size distribution, coupled with excellent nanoparticle and drug co-
encapsulation efficiency, is a very important fabrication parameter for the industrial 
production of microcapsules, ensuring their controlled and reproducible manufacture. 
Reliable and effective fabrication technologies able to satisfy all these parameters and assure 
economically adequate encapsulation efficiency (higher than 80%) remain a challenge. In 
fulfilling this objective, supercritical fluid technologies have been described that offer 
improved control over the morphology and composition of micro and nanoparticles42-44 (or 
biomaterial porosity)45. Among all the supercritical technologies described in the literature 
for micro and nanoparticle fabrication Supercritical Emulsion Extraction (SEE) was recently 
described as the most effective method for the fabrication of biopolymer microcapsules, due 
to the fact that it uses supercritical carbon dioxide for the fast extraction of the emulsion oily 
phase (oil-in-water or multiple water-oil-water) achieving the production of microcapsules 
with excellent encapsulation efficiency. This technology has recently been developed with a 
continuous process operation layout that assures a greater uniformity of product46-47.  
However, PLGA/PLA showed low potential to modify the surface properties to 
provide better interaction with biological materials. Recently, aqueous solutions of 
zwitterionic carboxybetaine derivatives have drawn special attention, due to their anti-fouling 
properties which have been shown to resist a wide variety of protein adsorption, biofilm 
formation and cell attachment48. Carboxybetaine also provides the capability of further 
biomaterial functionalisation49. The overall hydration property of carboxybetaine is ascribed 
to its ability to form hydrogen-bonded interactions with a range of organic and inorganic 
acids owing to a high electron density on its two carboxylic oxygen atoms. 
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The aim of this paper is to explore the performance of SEE in the fabrication of PLA 
and PLGA injectable microcapsules carrying superparamagnetic nanoparticles (MAG) loaded 
with fluorescein (Fluo), a typical fluorescent probe. The microdevices were coated with 
chitosan functionalised with carboxybetaine moieties to improve surface biocompatibility of 
the microsystem. Different emulsion compositions were processed by SEE to identify the 
best emulsion stability and formulation to obtain the highest encapsulation efficiency and an 
engineered drug release with or without the ability to control release remotely using an 
external magnetic field.  
 
MATERIALS & METHODS 
Materials  
CO2 (99.9%) was purchased from SON (Naples, Italy). Poly-Vinyl Alcohol (PVA, 
Mol wt: 30000–55000), poly-Sorbate (Tween 80), Fluorescein sodium salt (Fluo, water 
solubility 500 g/L), Iron Oxide nanoparticles (Fe3O2, mean size 6.5 nm ±3.0 nm; plus oleic 
acid, as stabilizer) were used in water suspension as received from Sigma-Aldrich Co., 
(Milan, Italy). Poly-lactic acid (PLA, RESOMER® RG 203H; Mol wt: 20.000) and Poly-
lactic-co-glycolic acid (PLGA 50:50, RESOMER® RG 504H, Mol. wt: 38000-54000) were 
obtained from Evonik Industries (Essen, Germany). Ethyl acetate (EA, purity 99.9%), was 
supplied by Carlo Erba Reagents (Milan, Italy).  
Emulsion preparation and Supercritical Emulsion Extraction apparatus 
Different water-oil-water (w1-o-w2) emulsions (ratio 1:19:80 w/w) were prepared to 
load MAG and/or Fluo into the biopolymer capsules, respectively. The oil phase was always 
prepared by dissolving 2 g of PLA or PLGA in 19 g of ethyl acetate. The internal water phase 
(w1) was of 1 mL of water/PVA solution (0.06 % w/w) with a fixed amount of MAG (2.5, 5, 
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10 mg) and/or Fluo (10 mg), respectively; the external water phase (w2) was 80 g of EA-
saturated water solution with Tween80 (0.6% w/w) in water. The primary emulsion (w1-o) 
was obtained by sonication for 1 min at 30% of tip sonicator amplitude (mod. S-450D, 
Branson Ultrasonics Corporation, Danbury, CT, USA); the w1-o emulsions were, then, 
immediately mixed into the external water phase by high-speed stirring (mod. L4RT, 
Silverson Machines Ltd., Waterside, CheshamBucks, UK) for 3 min at 3300 rpm. The 
emulsion stability was monitored by Optical Microscopy; stable emulsions were loaded into 
the column (height 1600 mm, internal diameter 10 mm) packed with stainless steel packings 
(Pro-Pak, 4 mm nominal size, 0.94 voidage) by high pressure piston pump (mod. 305, Gilson, 
France) at the top of the column and contacted to supercritical-CO2 pumped by a second high 
pressure diaphragm pump (mod. Milroyal B, Milton Roy) from the bottom. Before starting 
the emulsion delivery, the column was wetted with a fixed amount of the water phase. A 
separator located downstream at the top of the column was used to recover the extracted 
solvent. The nanocarrier suspension was continuously collected at the bottom of the 
extraction column using a needle valve, and washed with pure water by centrifugation prior 
their lyophilization.  
Droplet and microsphere morphology 
Droplets in the emulsion were observed using an optical microscope (OM, mod. BX 
50 Olympus, Tokyo, Japan) equipped with a phase contrast condenser. Microspheres shape 
and morphology were investigated by Field Emission-Scanning Electron Microscopy (FE-
SEM, mod. LEO 1525, Carl Zeiss SMT AG, Oberkochen, Germany) coupled with energy 
dispersive X-ray spectroscopy (EDX, INCA Energy 350, UK) and by the same FE-SEM 
equipped with an S-TEM detector (mod. Zees Ultra Plus, Carl Zees SMT AG, Oberkochen, 
Germany). For FE-SEM observation samples of powder were placed on a double-sided 
adhesive carbon tape previously stuck to an aluminum stub and coated with a thin chromium 
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film (layer thickness 250 Ǻ) using a sputter coater (mod.108 A, Agar Scientific, Stansted, 
United Kingdom). 
Chitosan functionalisation and microspheres coating  
Chitosan was dissolved in acetic acid and diluted 1:1 with methanol before N-succinylating 
with 4% (w/v) succinic anhydride in acetone solution (SC). This step was followed by the 
grafting of betaine monomers previously activated through reaction with 10X Molar excess 
N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydro-chloride (EDC) and 25X Molar 
excess N-hydroxysuccinimide (NHS) in 0.1M MES buffer pH 6.0. SC-B was desalted into 
dH2O using dialysis with 3.5kDa MWCO cellulose tubing and syringe filtered at 0.45µm 
before lyophilising. The synthesis of both the derivatised chitosan and final f-Chi was 
assessed by FTIR. Functionalisation was assessed on chitosan samples in powdered form 
using the Perkin Elmer Spectrum 65 with a universal ATR sampling accessory. A total of 8 
scans were obtained between 650 cm-1 and 4000 cm-1 (at 4 cm-1) per sample. 
To obtain f-chitosan-coated microdevices (f-ChiPLGA), the microcapsules, as 
recovered after the SEE process (at pH 3.9 due to the presence of CO2, still dissolved in 
water), were centrifuged and re-suspended in 50M acetic acid buffer to reach a chitosan 
solution of 0.4 mg/mL and incubated for 1 h at room temperature. After incubation, the 
uncoated chitosan was removed by an ultra-centrifugation and washing step in phosphate 
buffer at pH 7, repeated twice. 
Microcapsule size distributions and suspension Zeta-Potential 
Particle size distributions (PSD) were measured using a Mastersizer S apparatus (mod. 
Mastersizer S, Malvern Instruments Ltd., Worcherstershire, United Kingdom), based on 
dynamic light scattering (DLS). Analyses were performed immediately after the preparation 
of the emulsions and of the microsphere suspensions, using several milligrams of each 
sample, appropriately diluted with distilled water.  
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A Zetasizer (mod. NanoZS Malvern Inc., Wocherstershire, UK) equipped with a 5.0 
mW He-Ne laser operating at 633 nm was used for Zeta-Potential measurements. Samples 
were analyzed in glass cuvettes at 25°C and scattering angle of 173°; all the results are based 
on an average of 3 measurements, which was calculated on an average of 10 runs. Zeta-
Potential value expressed in mV indicates the potential difference between the dispersion 
medium and the stationary layer of fluid attached on the dispersed particle and is a key 
indicator of the dispersion stability.  
The electrical characteristics of free MAG and PLA/PLGA microcarriers were 
analyzed by electrophoresis measurements as a function of pH using the Malvern Zetasizer. 
In this assay, different solutions of NaCl (0.001M) in NaOH or HCl at pH values ranging 
from 3 to 11 were prepared using a pH meter (Mettler Toledo, France). Zeta potential of 
diluted suspensions was tested to determine the pH effect on the MAG loaded microapsules50. 
Solid state characterization  
MAG encapsulation efficiency was measured by thermogravimetric analysis (TGA), 
as the residue remaining after total combustion of the polymeric component of the particles. 4 
mg of each sample was placed in alumina crucibles and heated up to 600°C at a rate of 10 
°C/min, under a constant air flow of 50 N cm3/min. The infrared spectra were recorded with a 
Unicam Mattson 5000 FT-IR Spectrometer at room temperature. The spectra were taken in 
KBr discs in the range of 3500-400 cm−1. 
Drug loading and in vitro release study 
Fluo was measured fluorimetrically (λex 460 nm; λem 515 nm) using a  
spectrofluorimeter (mod. Infinite™ 200 series, InsTecan Group Ltd., Männedorf, 
Switzerland). Encapsulation Efficiency of Fluo was measured by dispersing an accurately 
weighed amount (approximately 20 mg) of microcarriers in 1 mL of acetone and then diluted 
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with 20 mL of distilled water. Encapsulation Efficiency (EE%) percentage was expressed as 
Fluo amount detected/Fluo amount loaded x 100.  
In vitro release data were obtained by suspending 20 mg of microcarriers in 3 mL of 
physiological solution at room temperature and stirred continuously. Every 24 h the samples 
were centrifuged at 2 g for 15 min and the supernatant was completely removed and replaced 
with fresh media to maintain sink conditions. Released Fluo concentrations from collected 
samples were then assayed fluorimetrically. Release experiments were performed in triplicate 
and curves are the mean profile obtained; error bars are also reported to better describe the 
data. Triggered release was monitored by weighting 20 mg of microdevices, dispersing them 
into 4 mL of physiological solution within a petri dish on top of the solenoid and subjected to 
an Alternating Magnetic Field (AMF) of strength 2.98 kA/m and frequency 297 kHz. The rise 
in surface temperature of nanocomposites was recorded by IR camera. The AMF was 
continued for 5 min and the released Fluo concentrations were assayed fluorimetrically. The 
experiment was repeated every hour and the Fluo released after the magnetic field exposure 
was then monitored by centrifuging at 2 g for 15 min, sampling the supernatant and replacing 
with fresh media.  
 
RESULTS AND DISCUSSION 
Microcarrier fabrication: operative SEE conditions,  
Microcarriers were produced by processing different emulsion formulations by SEE at 
operative pressure and temperature conditions of 9 MPa and 38°C, respectively, with a 
countercurrent SC-CO2 flow rate of 1.4 kg/h and an Liquid/Gas ratio of 0.1 on mass based46. 
The operative conditions used were selected in order to achieve a fast and complete 
extraction of ethyl acetate, the oily phase of the emulsion. Indeed, using these pressure and 
temperature conditions a complete miscibility between carbon dioxide and ethyl acetate is 
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obtained; whereas, no miscibility with the water external phase is possible. Moreover, under 
these conditions, carbon dioxide has a density of about 0.3 gcm-3 and a good density 
difference is assured between the gas and the liquid moving in a countercurrent fashion 
within the packed column; these operative conditions assured a fast, effective and complete 
ethyl acetate extraction after only 5 minutes of residence time in the apparatus. The SEE 
layout also allows the continuous recovery of the microdevices, so they have no chance of 
aggregating or re-organizing their structure. The operative pressure, temperature and flow 
rate ratio conditions described in this work are different from those described by Furlan et 
al.39 where the authors reported the production of magnetic nanocomposites in a PLGA 
matrix via supercritical fluid extraction of emulsion. In addition, they used a different process 
layout that works in a semi-continuous arrangement that involves two streams mixed by 
spraying them with two nozzles at the inlet of the reactor. In this configuration, the particles 
remain suspended in the water phase throughout the whole process and they are recovered 
only after reactor depressurization, therefore some rearrangements and aggregation of the 
particles are possible.  
Microcarrier sizes and loadings 
Figure 1 shows the SEM micrographs of PLGA and PLA microcarriers; they are 
spherical, with mean sizes ranging between 800 and 900 nm and a standard deviation not 
higher than 10% of the mean value; their mean sizes did not show any influence with respect 
to different MAG loadings. Emission Differential X-ray-Scanning Electron Microscope 
(EDX-SEM) analyses suggested a good iron dispersion within the biopolymer matrix, as 
illustrated in Figure 2, where the red map in the micrograph indicates iron atomic X-ray 
emission (the data reported refers to PLGA/MAG loaded at 2.5 mg/g). Good encapsulation 
efficiency was also suggested from the iron percentage calculated by the X-ray emissions. In 
Figure 3 TGA traces are reported to describe the thermal behavior of three different carrier 
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formulations from which was calculated the iron oxide amount after samples were heated to 
750°C. Encapsulation Efficiency was 99% for all PLGA samples and 90% for PLA devices. 
Mean sizes (MSs) and standard deviation (SDs) of all the prepared devices with different 
MAG loading are listed in Table 1, together with the nominal MAG loading and the 
measured values.  
The MAG loaded within the polymer matrix was also clearly detected by FT-IR. 
Indeed, as illustrated in Figure 3, the FT-IR spectra of the different formulations fabricated 
showed the characteristic absorption peak for Fe3O4 at 580 cm−1 in agreement with other 
works51, and those of the poly-esters that are evident at about 1750 cm−1 (carbonyl groups), 
1080 cm−1 (C–O–C stretching bands) and 1450 cm−1 (C–H stretching in methyl groups).  The 
IR traces therefore confirmed a good dispersion and encapsulation of magnetite within the 
matrix of the PLGA and PLA devices fabricated by SEE. All the emulsion formulations 
tested here provided improved encapsulation efficiency when compared with those reported 
in the literature31,39.  
The excellent encapsulation efficiency obtainable by SEE processing is due to the 
short residence time of the emulsion/suspension in the high pressure packed column that 
caused fast polymer hardening. However, when the amount of magnetite loaded was more 
than 5 mg/g, evident nanoparticle agglomerates on the microcarrier surface were observed by 
SEM, suggesting ineffective entrapment; as a consequence, only microdevices with a MAG 
loading below 5 mg/g will be further discussed. This result seemed somewhat in contrast with 
those reported by Liu et al.32 that described biopolymer microcarriers with a magnetite 
content of 40-60%; however, distorted surface morphology was always reported by the 
authors. In our case, to assure a triggered release, MAG loading between 0.5-1% were 
selected, also to avoid the stronger thermal side effect that higher MAG loading may have.  
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Carriers Surface stability 
Surface charge is one of the most important parameters governing tissue uptake of 
particles. Zeta Potential is a useful indicator of surface charge, and it can be employed as an 
index reflecting the stability of the microdevices obtained. Moreover, it has been mentioned 
that the surface properties of magnetite are extremely sensitive to pH fluctuations. However, 
such properties should not be found when magnetite crystals are well encapsulated in the 
interior of PLA or PLGA nanoparticles. Thus, we investigated the influence of pH on the 
Zeta-potential in water suspension for all of the SEE produced microcarriers. Synthesized 
magnetite crystals show an obvious isoelectric point in the vicinity of pH 6.7 accompanied by 
a negative potential in alkaline pH medium and a positive one in acidic pH medium50. This 
data was confirmed and demonstrated in Figure 4 (see black square dots). However, surface 
charges of the magnetic microcarriers (for all the formulas tested with PLA and PLGA) were 
not influenced by the pH values as also illustrated in Figure 4, where the zeta potential of 
particles was found to be less positive (negative) than that of magnetite at acid (basic) pH 
values. This leads to the confirmation that magnetite is very well encapsulated within the 
microdevices. 
f-Chitosan coating  
FTIR spectra of functionalized chitosan showed a reduction of the peaks attributed to the 
primary amine groups (peak 1564 cm-1) of the chitosan following the chemical grafting of the 
betaine molecules. Further evidence to support the successful grafting of these 
carboxybetaine moieties on the material was provided by the increased methyl peak 
formation at 2937 cm-1 (consistent in the betaine only spectra), and in the aliphatic amine 
region of peaks between 1020 cm-1 and 1220 cm-1 (see also Figure 3) 
f-Chi was used to coat MAG loaded PLA and PLGA microcarriers at concentrations 
of 0.4 mg/mL, and the resulting Zeta-potentials of these coated microspheres were also 
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compared to those of the uncoated samples. Indeed, the uncoated PLA and PLGA 
nanoparticles showed a negative Zeta Potential at pH 4.75 of -8.1± 1.2 mV; when they were 
covered with f-chitosan the Z-Potential value increased up to 26 ± 1.2 mV at pH of 5.5 for 
both samples (see red and blue rhombus in Figure 4). This inversion of Zeta potential 
towards positive values demonstrated the successful coating of the beads whereby f-Chi 
exposing carboxybetaine and remaining non-functionalised amino groups of chitosan 
contribute to the change of surface charge. In both cases, the adsorption of chitosan occurred 
spontaneously, with no aggregation of the colloids. 
In Figure 5 an FE-SEM image and a TEM image of PLGA carriers loaded with MAG 
at 5 mg/g and coated with f-chitosan are illustrated; the coating did not alter the spherical 
shape of the structure, but generated slightly irregular carrier surfaces. FE-SEM images of 
PLA coated microdevices loaded with MAG at 5 mg/g are also illustrated in Figure 5. The 
covered microcapsules also showed an increase in mean size from 921 nm to 1100 nm in the 
case of PLGA and from 839 nm to 1098 nm in the case of PLA microdevices, as represented 
by the histograms reported in Figure 5, where the PSDs of the coated and uncoated devices 
are compared, for both PLGA and PLA formulations. No increase in the size distribution was 
monitored. From the mean size increases the chitosan layer was calculated to range between 
100-125 nm. The f-chitosan coating improved MAG encapsulation efficiency that was 
measured at 99% for both PLGA and PLA devices. It can be speculated that the chitosan 
coating (performed just after SEE processing) prevents a washing off for the MAG 
nanoparticles (9-10% of the loading) present on the microcarrier surface by facilitating their 
stronger adhesion to the microcarrier surface. The improved drug loading efficiency can also 
be ascribed to the ability of carboxybetaine to entrap solutes by their highly hydrated 
molecular structure via hydrogen bonding52. 
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Sustained release 
The cumulative amount of Fluo released (%) vs. time (days) from uncoated and f-
chitosan coated PLGA microspheres is illustrated in Figure 6. Experimental points over the 
complete assay time are presented in the scatter plot with the standard deviation (three 
replicates were performed). Almost 60% of loaded Fluo was released in the first day; this 
“burst” effect is typical for small and highly water soluble molecules loaded in less than 1 
micron devices. From day two, Fluo showed a sustained release, with an amount of 8% of the 
load released each day for the following 5 days. The f-Chi coating reduced to one half the 
Fluo “burst” release, and further delayed the overall release of the Fluo. Indeed, only 34% of 
the loaded molecule was released in the first day, followed by a slower release of 5.5%/day of 
the loaded amount. From the coated microdevice, two thirds of the Fluo load was released per 
day when compared to the uncoated devices and, therefore, the total release time was 
increased to 10 days. The reduction of the bust release and the slower overall Fluo release 
observed for the f-Chi coated devices can again be speculated to be further controlled by 
carboxybetaine and its ability to entrap solutes within their highly hydrated molecular 
structure. 
Triggered release by Alternating Magnetic Field (AMF) 
Magnetite nanoparticles with a size generally less than 30 nm exhibit super 
paramagnetism53. Thus, the encapsulated magnetite was expected to have superparamagnetic 
properties and the produced microspheres were exposed to an AMF to demonstrate remote 
control release. In detail, microdevices with different compositions, PLGA, f-chiPLGA and 
PLA all loaded with 8 mg/g of Fluo and 4 mg/g of MAG, were exposed to an AMF and the 
amount of Fluo released are plotted in Figure 6, against time; the AMF input is also shown. 
All microcarriers performed an on-off release of the loaded Fluo. MAG/PLGA microdevices 
showed a triggered release with 40%, 30% and 20% of the encapsulated Fluo released during 
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the first 3 spots; whereas, a lower amount of Fluo was released in each of the first three spots 
from the coated f-chiPLGA (36%, 28% and 10%, respectively) suggesting that the f-Chi 
coating reduced the dose emitted in each spot. The PLA nanocarrier released an amount 
between 25 and 18 % of the loaded Fluo in the first three spots, and then 10% of the loaded 
molecules for the subsequent three spots. The results indicated that a good remote control 
release was obtainable from the described microdevices and the possibility of engineering the 
amount delivered in each spot varied according to the microcarrier formulation.   
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CONCLUSIONS AND PERSPECTIVES 
The advantage of the proposed approach is the combination of the emulsification 
method with the use of the supercritical fluid technology that offers a robust and fast way to 
fabricate engineered microcarriers, with excellent encapsulation efficiency and good 
magnetic nanoparticle dispersion within the biopolymer matrix. The approach also proposed 
an effective carboxybetaine-functionalized chitosan coating of the microcarriers that opens 
new routes of investigation for a controlled release of drugs combined with enhanced 
biocompatibility properties. 
However, the behaviors of the microsystems proposed were described in vitro by 
using a simulated physiological medium with microspheres always well dispersed. As we 
move to an in vivo biological environment, specific surfactants and/or additives have to be 
considered for the injectable formulation in order to assure the good dispersion of the locally 
hosted microsystems and to prevent large particle aggregation that may eventually occur54-55. 
Therefore, further studies will involve an in vivo testing of the formulation proposed on 
animal models with a specific follow up that will also include the post-mortem microscopy as 
a primary technique for qualitatively assessing the state of dispersion of the microsystem 
proposed. 
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FIGURE CAPTIONS 
Figure 1. Field Emission-Scanning Electron Microscope (FE-SEM) images of PLGA and 
PLA microcarriers loaded with different MAG amounts. The microcarriers consistently 
showed spherical morphologies  and mean sizes between 995-983 nm for PLGA and 837-853 
nm for PLA. FE-SEM images of the empty devices are also reported for the purpose of 
comparison. 
Figure 2. Emission Differential X-ray-Scanning Electron Microscope (EDX-SEM) image of 
PLGA microcarriers loaded with MAG at concentrations of 2.5 mg/g; single element maps 
related to iron (red), oxygen (light blue) and carbonium (green) are also shown. MAG 
nanoparticles showed uniform dispersion within the biopolymer devices (see red signals on 
SEM image) coupled with good encapsulation efficiency, as indicated from the iron 
concentration percentage calculated by the instrument.  
Figure 3. TGA and FT-IR traces of PLGA/MAG and PLA/MAG and f-chitosan (f-chi) 
coated capsules. The thermal behavior was used to calculate the iron oxide loading after 
samples were heated to 750°C for the different formulations. Encapsulation Efficiency was 
99% for all PLGA and 90% for PLA samples. FT-IR traces of different formulations 
consistently revealed the characteristic absorption peak for Fe3O4 at 580 cm−1 and those for 
poly-esters at about 1750 cm−1 (carbonyl groups), 1080 cm−1 (C–O–C stretching bands) and 
1450 cm−1 (C–H stretching in methyl groups). The f-chitosan covering provided 
carboxybetaine moieties on the material with the slightly increase of methyl peak at 2937 cm-
1
. 
Figure 4. Zeta-Potential values of PLGA and PLA microcarriers suspension loaded with 
MAG at different pH; pure F3O3 nanoparticles suspensions, empty and f-chitosan coated 
carrier suspensions are also reported for comparison.  
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Figure 5. Field Emission-Scanning Electron Microscope (FE-SEM) images of PLGA and 
PLA carriers loaded with MAG and coated with f-Chitosan; the coated carrier preserved the 
spherical shape (upper side). Histograms representing the Particle Size Distribution of coated 
and uncoated PLGA and PLA microcapsules also loaded with MAG (5 mg/g for PLGA; 4 
mg/g for PLA): the coated particles showed a mean size increase of 0.2 µm (lower left side). 
Transmission Electron microscope (TEM) image of the PLGA microcarrier, with the 
evidence of MAG loaded within (white spots) and the f-Chitosan coating that generate 
slightly irregular surface (lower right side).  
Figure 6. Release profiles from PLGA and f-Chi/PLGA microspheres loaded with 
fluorescein in PBS medium at 37°C (left side); triggered release from PLGA/MAG, f-
Chi/PLGA/MAG and PLA/MAG microcapsules all loaded with the same amount of 
Fluorescein (8 mg/g) and with the same content of MAG (4 mg/g) in PBS medium at 37°C by 
Alternating Magnetic Field (AMF) (right side). 
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Table 1. List of microcapsules produced by SEE, mean size (MS) and standard deviation (±), 
drug encapsulation efficiency expressed as percentage (EE%) and drug real loadings 
expressed as mg/g (g is referred to the amount of biopolymer contained in the product); Z-
Potential (Zp) values measured at pH 5.5. MAG: iron oxide nanoparticles; Fluo: fluorescein; 
f-Chi: functionalized chitosan. 
Microcapsule composition  MS (nm) 
Mag 
(EE%) 
Mag 
(mg/g) 
Fluo 
(EE%) 
Fluo 
(mg/g) 
Zp pH 5.5 
(mV) 
PLGA/MAG   880 (±104) 99 1.2 -- -- -3.01 
PLGA/MAG  995 (±126) 99 2.5 -- -- -5.6 
PLGA/MAG  971 (± 118) 99 5 -- -- -4.2 
PLGA/MAG/Fluo  983 (±148) 99 5 78 7.8 -5.5 
PLA/MAG   837(±119) 90 1 -- -- -4.1 
PLA/MAG   828 (±124) 90 2 -- -- -2.1 
PLA/MAG  853 (± 108) 90 4 -- -- -2.6 
f-chi-PLGA/MAG  1103 (± 110) 99 5  -- 31.7 
f-chi-PLGA/MAG/Fluo  1114  (± 130) 99 5 80 8.0 34.5 
f-chi-PLA/MAG  1098 (± 118) 99 5 -- -- 27.7 
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